Neutrophils are among the first immune cells recruited when bacteria, viruses, or other pathogens invade tissue. They normally circulate in the bloodstream, but chemical signals released during infection prompt them to exit blood vessels and move through surrounding tissue. Once they reach their target, neutrophils can engulf microbes and release enzymes, reactive oxygen compounds, and antimicrobial proteins. These substances are highly effective against pathogens, but they can also injure healthy cells if released in the wrong place or at the wrong time. How neutrophils navigate complex tissue environments without triggering this destructive response prematurely has remained an important question in immunology.

The new study identifies a short-lived lipid mediator called hepoxilin A3 as a key directional signal. Infected or inflamed epithelial cells can release hepoxilin A3, creating a chemical gradient that extends from the affected tissue. Neutrophils detect this gradient through a membrane protein known as transient receptor potential vanilloid 2, or TRPV2. Rather than functioning simply as an on-or-off receptor, TRPV2 appears to provide directional information, helping cells interpret where the signal is strongest and adjust their movement accordingly.

The researchers found that TRPV2 interacts with the type 2 cannabinoid receptor, CB2R, on the neutrophil surface. Together, the two receptors form a signaling complex that coordinates cellular movement in response to hepoxilin A3. This interaction influences the internal signaling pathways that regulate the neutrophil cytoskeleton, the dynamic structural network that allows the cell to extend protrusions, change shape, and crawl through tissue. By coupling detection of the chemical signal to changes in cell polarity and motility, the receptor complex helps neutrophils move selectively toward the source of infection.

The mechanism also appears to determine when neutrophils should remain restrained. Earlier work from the research team showed that activation of CB2R by naturally occurring endocannabinoids can inhibit hepoxilin A3-driven migration. In this context, CB2R acts as a molecular brake, reducing unnecessary neutrophil movement when there is no strong indication of an active infection. When TRPV2 binds to CB2R in response to hepoxilin A3, however, the receptor system switches functional states. The brake is released, allowing the neutrophil to pursue the infection-associated signal.

This coordinated behavior may explain how neutrophils avoid causing widespread tissue injury during their journey. According to the study, migrating cells do not release their most damaging antimicrobial substances while traveling toward the source of hepoxilin A3. Instead, they remain in a controlled state until they reach the appropriate tissue location. Once they arrive, they can deploy a concentrated mixture of chemical weapons against invading microbes. The separation between navigation and attack gives the immune response both speed and spatial precision.

The discovery has implications for diseases in which neutrophils respond to misleading or excessive signals. In chronic inflammatory disorders of the gut and lungs, neutrophils may accumulate in tissues even when no active pathogen requires elimination. Their antimicrobial activity can then damage the body’s own cells, perpetuating inflammation and contributing to progressive disease. Similar processes are involved in conditions such as peritonitis and pancreatitis, where uncontrolled immune activation can produce severe tissue injury.

Most existing anti-inflammatory medicines work by broadly reducing immune signaling. Although this approach can relieve symptoms, it may also weaken protective immune responses or produce effects in organs that are not involved in the disease. The researchers propose that interfering specifically with the hepoxilin A3–TRPV2/CB2R pathway could provide a more selective alternative. A drug designed to block the directional signal or disrupt its receptor complex might prevent inappropriate neutrophil recruitment while preserving the cells’ ability to fight infections through other pathways.

Professor Randy Mrsny of the University of Bath, who co-led the study with Professor Beth McCormick of UMass Chan Medical School, compared neutrophils to biological bombs that should detonate only after reaching their intended target. The team’s findings suggest that the TRPV2 and CB2R system helps determine when these cells should move, stop, change direction, and release their antimicrobial contents. The researchers will next investigate how the hepoxilin A3 signaling pathway can be selectively blocked and whether such interventions can be developed into targeted anti-inflammatory drug candidates. The work does not yet represent a clinical treatment, but it offers a detailed molecular framework for restoring precision to immune responses without disabling the body’s ability to defend itself.

Subject of Research: Cells

Article Title: Transient Receptor Potential Vanilloid 2 Functions as a Directional Driver for Hepoxilin A3-Mediated Neutrophil Migration

News Publication Date: 31-Jul-2026

Web References: https://www.science.org/doi/10.1126/sciadv.adz1986

References: Science Advances, DOI: 10.1126/sciadv.adz1986

Keywords: Neutrophils, TRPV2, CB2R, hepoxilin A3, immune cell migration, inflammation, chronic inflammation, anti-inflammatory drugs, infection, immunology

ARDS is clinically devastating, arising from diverse triggers such as pneumonia, severe viral infections including COVID-19, and sepsis. It manifests through the accumulation of protein-rich fluid in alveoli, which severely disrupts oxygen absorption. Despite advances in supportive care, mortality rates linger between 30% and 50%, underscoring the urgent need for innovative therapeutic strategies. Against this backdrop, the Institute of Science Tokyo’s research delineates an immunological pathway that could be harnessed to modulate inflammation resolution and improve patient outcomes.

Employing a rigorous experimental model, the investigators induced ARDS in mice via intratracheal administration of lipopolysaccharides (LPS), bacterial components known to trigger robust lung inflammation mimicking human disease. Comparative analyses between basophil-deficient and wild-type mice revealed stark differences during the recovery phase: mice lacking basophils exhibited extensive pulmonary injury, elevated neutrophilic infiltration, and sustained inflammatory responses. These results underscore basophils’ unanticipated yet critical immunoregulatory function beyond their classical role in allergy.

At the molecular level, single-cell RNA sequencing illuminated the mechanistic underpinnings of basophil-mediated resolution. Basophils in inflamed lung tissue were identified as a predominant cellular source of IL-4, a signaling molecule that orchestrates immune modulation. Genetic ablation of IL-4 production specifically in basophils exacerbated lung pathology and fluid retention during convalescence, affirming IL-4’s essential role. Mechanistically, IL-4 acts directly on neutrophils, downregulating the expression of genes that drive pro-inflammatory cytokine production—namely Il1a, Il1b, and Cxcl2—and genes that inhibit apoptosis such as Bcl2a1 family members. Through this modulation, IL-4 curtails neutrophil longevity and inflammatory potential, accelerating the resolution of lung injury.

This paradigm shift redefines basophils from being stigmatized as ‘bad actors’ to critical ‘good actors’ that enforce immunological balance during ARDS recovery. The discovery aligns with clinical observations linking low peripheral basophil counts to worse respiratory failure outcomes in septic and COVID-19 patients, providing a potential cellular biomarker for disease prognosis. Moreover, it opens intriguing avenues for therapeutic intervention by targeting the basophil–IL-4–neutrophil axis to attenuate inflammation without compromising host defense.

The implications of these findings reach far beyond basic immunology, touching the core challenges of translational and clinical medicine. Current ARDS management remains supportive with no FDA-approved pharmacotherapies to directly promote resolution of lung inflammation. The ability to harness or mimic basophil-derived IL-4 signaling might revolutionize treatment paradigms, offering a targeted approach to dampen neutrophil-driven tissue injury while preserving essential immune functions. However, the research team cautions that the cellular sources of IL-4 in human ARDS cases remain to be elucidated, highlighting a critical knowledge gap that future investigations must address.

Basophils representing merely 0.5 to 1% of circulating leukocytes have historically received limited attention due to their perceived subordinate role in immune responses. Yet this study contributes to an evolving appreciation of basophil plasticity, revealing their capacity to produce immunomodulatory cytokines and participate dynamically in inflammatory environments. Prior studies demonstrated basophils’ involvement in resolving skin inflammation and bacterial infections, but this ARDS context extends their relevance to critical pulmonary pathology.

The elucidation of the transcriptional changes governed by IL-4 in neutrophils further enriches our understanding of inflammation biology. Pro-inflammatory mediators such as IL-1α, IL-1β, and CXCL2 perpetuate neutrophil recruitment and activation, often leading to a deleterious feedback loop of tissue destruction and chronic inflammation. By repressing these factors, IL-4 effectively ‘reprograms’ neutrophils towards a less harmful phenotype and facilitates programmed cell death, which is essential for clearing inflammatory infiltrates. This mechanistic insight highlights potential molecular targets that could be leveraged pharmacologically.

Integral to this investigation was the application of single-cell RNA sequencing—an advanced technology that allows dissection of the heterogeneous immune cell milieu within the ARDS-injured lung at unprecedented resolution. This approach enabled precise identification of cellular contributors to cytokine landscapes and provided novel biomarkers of disease trajectory. The multidisciplinary team, spanning immunology, pulmonary medicine, and molecular biology expertise, exemplifies the collaborative approach required to unravel complex disease processes.

While the findings herald promising advances, translation from murine models to human clinical scenarios necessitates careful validation. Human ARDS arises from multifactorial etiologies and encompasses intricate immunopathology, thus future research must clarify whether basophils and IL-4 exert comparable protective roles in patients. Additionally, the prospects of modulating basophil function or IL-4 signaling raise questions about potential off-target effects, especially given IL-4’s known roles in allergy and asthma.

In summary, this landmark study reframes our immunological understanding of ARDS resolution, positing basophils and their secretion of IL-4 as key drivers that attenuate neutrophil-mediated lung inflammation. The delineation of this pathway not only fills a critical gap in ARDS pathogenesis but also paves the way for innovative therapies aimed at improving the dismal survival rates associated with this syndrome. As the global health community grapples with respiratory pandemics and severe inflammatory lung diseases, insights such as these are invaluable in steering the future direction of biomedical research and clinical care.

Subject of Research: Animals

Article Title: Emerging roles of basophils in the resolution of the acute respiratory distress syndrome

News Publication Date: 31-Jul-2025

Web References: https://doi.org/10.1183/13993003.01150-2024

Image Credits: Institute of Science Tokyo

Keywords: Immunology, Respiratory disorders, Basophils, Neutrophils, Inflammation, Cytokines, Molecular biology, Infectious diseases, Translational medicine, Blood cells